Black Farmers in Brazil Changing Views on Coffee Production

Many in Brazil still associate coffee production with slavery. Douglas Magno / AFP
Many in Brazil still associate coffee production with slavery. Douglas Magno / AFP
TT

Black Farmers in Brazil Changing Views on Coffee Production

Many in Brazil still associate coffee production with slavery. Douglas Magno / AFP
Many in Brazil still associate coffee production with slavery. Douglas Magno / AFP

Raphael Brandao beams with pride as he describes the high-end Brazilian coffee he produces with beans sourced exclusively from Black farmers in a country where many still associate the product with slavery.
The 31-year-old buys his coffee beans solely from farms owned by Afro-descendents and says his goal is to "reverse this logic that Black people" like himself "are mere laborers”.
"In my own way, I am trying to make historical reparations," Brandao told AFP at his roastery in Nova Iguacu, a poor suburb of Rio de Janeiro.
Four years ago, he launched his brand Cafe di Preto.
By 2022 he sold 800 kilograms (about 1,700 pounds), the following year 1.4 tons. This year he hopes to increase that to more than two tons following a 20-percent sales increase in the first quarter alone.
The logo for Cafe di Preto is a raised Black fist clutching a coffee branch, and the different flavor lines are each named after important Black women of Brazilian history.
Brazil was the last country in the Americas to abolish slavery, in 1888, and racial inequalities remain high in a country where more than half of people identify as "preto" (Black) or mixed-race.
'Changing the world'
He is also seeking to "break the stigma that Black people do not produce quality."
"So my work also gives light to this," he said. "Today I have six coffees produced by Black people, all of them... of great quality."
Many of his clients, he added, are looking for quality but also for a product that is "changing the world."
Brandao is a leader in the so-called Black Business wave in Brazil that promotes commerce among people of African descent as a tool for social progress.
At first, he had trouble finding Black suppliers given that the overwhelming majority of coffee plantations in Brazil still belong to white families.
"My black suppliers are the first generation to produce on their own land, often only a few hectares," he said.
And Brandao has more than once had to defend his chosen crusade.
"I am sometimes asked: 'What if it was the opposite, if roasteries owned by whites bought coffee from white farmers?' But isn't that what is happening already?"
From farm to cup
About 500 kilometers (311 miles) from Nova Iguacu is the 19-hectare (47-acre) coffee plantation of Neide Peixoto, one of Brandao's first suppliers.
"I have been in contact with coffee since childhood. My parents worked in crops and I often accompanied them," Peixoto, 49, told AFP on her farm in the southeastern state of Minas Gerais, a mecca for coffee production.
Unlike her parents, she grows coffee on land that belongs to her own family, bought by her husband and brothers who are also former laborers.
"It means a lot to me to be a Black producer of special coffee, because... we, Black people, have a very difficult and painful history," Peixoto said.
Most of the farm's production is for export, but the beans reserved for Cafe di Preto have a special significance for Peixoto.
"It's exciting to know that the coffee I produce, which is coffee produced by Black people, is also roasted by Black people," she said.
"I'm very happy to know that we are making this connection, from production here on the farm to the cup."



Weight-Loss Drugs May Lower Cancer Risk in People with Diabetes, a Study Suggests 

A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. (Reuters) 
A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. (Reuters) 
TT

Weight-Loss Drugs May Lower Cancer Risk in People with Diabetes, a Study Suggests 

A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. (Reuters) 
A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. (Reuters) 

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention.

Now, a study of 170,000 patient records suggests there's a slightly lower risk of obesity-related cancers in US adults with diabetes who took these popular medications compared to those who took another class of diabetes drug not associated with weight loss.

This type of study can't prove cause and effect, but the findings hint at a connection worth exploring. More than a dozen cancers are associated with obesity.

“This is a call to scientists and clinical investigators to do more work in this area to really prove or disprove this,” said Dr. Ernest Hawk of MD Anderson Cancer Center in Houston, who was not involved in the study.

The findings were released Thursday by the American Society of Clinical Oncology and will be discussed at its annual meeting in Chicago. The study, funded by the National Institutes of Health, was led by Lucas Mavromatis, a medical student at New York University’s Grossman School of Medicine.

“Chronic disease and chronic disease prevention are some of my passions,” said Mavromatis, a former research fellow with an NIH training program.

GLP-1 receptor agonists are injections used to treat diabetes, and some are also approved to treat obesity. They work by mimicking hormones in the gut and the brain to regulate appetite and feelings of fullness. They don't work for everyone and can produce side effects that include nausea and stomach pain.

In the study, researchers analyzed data from 43 US health systems to compare two groups: people with obesity and diabetes who took GLP-1 drugs and other people with the same conditions who took diabetes drugs like sitagliptin. The two groups were equal in size and matched for other characteristics.

After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk of death from any cause compared to those who took the other type of diabetes drug. There were 2,501 new cases of obesity-related cancer in the GLP-1 group compared to 2,671 cases in the other group.

The effect was evident in women, but not statistically significant in men. The study couldn't explain that difference, but Mavromatis noted that differences in blood drug concentration, weight loss, metabolism or hormones could be at play.